A Multicentre, Open-label Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (≥37 Weeks and <41 Weeks of Gestation) Requiring Cervical Ripening
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
Price : $35 *
At a glance
- Drugs Dinoprostone (Primary)
- Indications Labour induction
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 07 Mar 2018 Status changed from recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.